Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | PYGL | P06737 | 2/20 | 0.50 |
| ▸ | PYGM | P11217 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7122269 | 0.86 | PYGL (0.54) | MEN1KMT2AMAPTALDH1A1PYGL | |
| SCHEMBL4094329 | 0.82 | KMT2A (0.66) | MEN1KMT2AMAPTALDH1A1ABCG2 | |
| SCHEMBL7122268 | 0.81 | KMT2A (0.56) | MEN1KMT2AMAPTALDH1A1PYGL | |
| SCHEMBL7118343 | 0.80 | ABCG2 (0.54) | MEN1KMT2AMAPTALDH1A1PYGL | |
| SCHEMBL6431792 | 0.79 | PYGL (0.78) | MEN1KMT2AMAPTPYGLPYGM | |
| SCHEMBL6430903 | 0.78 | MEN1 (0.53) | MEN1KMT2AMAPTALDH1A1PYGL | |
| SCHEMBL5834186 | 0.78 | KMT2A (0.63) | MEN1KMT2AMAPTALDH1A1PYGL | |
| SCHEMBL7116495 | 0.78 | KMT2A (0.53) | MEN1KMT2AMAPTALDH1A1PYGL | |
| SCHEMBL7117003 | 0.74 | MEN1 (0.65) | MEN1KMT2AMAPTALDH1A1PYGL | |
| SCHEMBL7126565 | 0.74 | MAPT (0.67) | MEN1KMT2AMAPTALDH1A1PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186944-A1 | Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics | KRISTIANSEN MARIT (DK) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186944-A1 | Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics | PYGL, GYS2, PYGM | MEN1 2301/4885KMT2A 971/4885MAPT 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.